Summary
This prediction ended on 09.11.18 with a price of €18,400,000. The BUY prediction by melinda for Neovacs performed very badly with a performance of -33.33%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Neovacs | - | - | - | - |
| iShares Core DAX® | -6,02 % | -4,60 % | 1,28 % | 48,46 % |
| iShares Nasdaq 100 | 0,51 % | 0,16 % | 14,40 % | 85,25 % |
| iShares Nikkei 225® | -7,16 % | -2,21 % | 27,89 % | 50,35 % |
| iShares S&P 500 | -0,26 % | -0,84 % | 10,25 % | 58,65 % |
According to melinda what are the pros and cons of Neovacs for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Neovacs diskutieren
(Vom Mitglied beendet)